The aim of this study is the calculation of equivalent organ dose and estimation of lifetime attributable risk (LAR) of cancer incidence and mortality related to cardiac computed tomography angiography (CCTA) because the use of CT angiography as a noninvasive diagnostic method has increased. The organ dose has been calculated by ImPACT software based on the volumetric CT dose index (CTDIvol), and LAR of cancer risk incidence and mortality from CCTA has estimated according to the BEIR VII report. The median value of the effective dose was 13.78 ± 6.88 mSv for both genders. In all scanners, the highest median value for LAR of cancer incidence in males and females for lung cancer was 44.20 and 109.17 per 100 000, respectively. And in infants was 5.89 and 12 for lung cancer in males and breast cancer in females, respectively. Also, the median value of LAR of all cancer incidence from single CCTA in adult patients for males and females was 122 and 238 cases, respectively. Maximum LAR of cancer mortality in adults for lung cancer was 40.28 and 91.84 and in pediatrics was 5.69 and 8.50 in males and females, respectively. Despite many benefits of CTA in the heart disease evaluation, according to a high radiation dose in CCTA, to reduce the cancer risk: CCTA should be used cautiously, especially for pediatric and females.

中文翻译：

---

与心脏 CT 血管造影相关的器官等效剂量和终生可归因的癌症发病率和死亡率风险。

本研究的目的是计算等效器官剂量并估计与心脏计算机断层扫描血管造影 (CCTA) 相关的癌症发病率和死亡率的终生归因风险 (LAR)，因为 CT 血管造影作为一种无创诊断方法的使用已经增加。器官剂量由 ImPACT 软件根据体积 CT 剂量指数 (CTDIvol) 计算，CCTA 癌症风险发生率和死亡率的 LAR 已根据 BEIR VII 报告估算。两种性别的有效剂量的中值为 13.78 ± 6.88 mSv。在所有扫描仪中，男性和女性肺癌癌症发病率的最高中值分别为每 10 万人 44.20 和 109.17。在婴儿中，男性肺癌和女性乳腺癌分别为 5.89 和 12。还，男性和女性成年患者单次 CCTA 的所有癌症发病率的 LAR 中值分别为 122 和 238 例。成人肺癌癌症死亡率的最大 LAR 为 40.28 和 91.84，儿科男性和女性分别为 5.69 和 8.50。尽管 CTA 在心脏病评估中有许多好处，但根据 CCTA 中的高辐射剂量，为了降低癌症风险：CCTA 应谨慎使用，尤其是对儿童和女性。